effects of tadalafil did not interfere with the antitumor effect of DOX in killing human osteosarcoma cells in vivo or in vitro.
An even more exciting observation was reported in a recent article 4 in which androgen-independent prostate cancer cell lines PC-3 and DU145 cells were studied. Concomitant treatment of these cancer cells with both sildenafil and DOX reduced the DOX-induced toxicity and left ventricular dysfunction in the normal cells and hearts as had been previously demonstrated by the Kukreja group. 2, 3 Intriguingly, this same combined drug treatment demonstrated an additive or synergistic effect of sildenafil and DOX, an increased apoptosis of androgen-independent prostate cells, and a reduction in prostate tumor xenografts in mice. Sildenafil had no effect on prostate cancer cells or normal epithelial cell lines (PrEC) when administered alone. These same investigators also showed that the combination of DOX and sildenafil was also synergistic in killing sarcoma and ovarian cells, 4 which suggests that sildenafil may play a broad role in promoting the activity of anticancer drugs against several forms of cancer. Interestingly, DOX-induced apoptosis occurred in PC-3 and DU145 cells as a result of increased reactive oxygen species (ROS), upregulation of caspase-3 and caspase-9 activity, a reduced expression of the antiapoptotic protein, Bcl-xL, and phosphorylation of Bad. These data are impressive, and the mechanism for the sensitizing effect of sildenafil to enhance the antitumor activity of DOX remains unknown, based on the results of the current study. Future studies addressing the mechanisms responsible for this interesting drug-drug interaction are necessary and worth pursuing. These studies should be extended to other PDE5 inhibitors to determine if this effect is unique to sildenafil or whether it is a class effect of PDE5 inhibition, in general. Additionally, future studies should also include ones performed in androgen-sensitive prostate cell lines, such as LNCaP cells, because results obtained in these cells may be more indicative of what one would expect in prostate cancer in vivo. These present results suggest that a new treatment paradigm may be on the horizon for the safer use of doxorubicin in cancer chemotherapy. One potential candidate for the site of action for this sensitizing effect of sildenafil in the presence of DOX, suggested by data obtained in previous studies and the current study, may be mitochondrial ROS. 5 It is known that DOX produces high concentrations of mitochondrial ROS in tumor cells 5 and that the combination of sildenafil and DOX produces even greater amounts of ROS, which may be at least partially responsible for the enhanced cell death in the cancer cells. 4 In contrast, the combination of DOX and sildenafil actually resulted in a decrease in ROS production in normal cells, as demonstrated in the present study. These findings may be important in understanding the mechanisms responsible for the beneficial effects of sildenafil and other PDE5 inhibitors on DOX-induced cardiotoxicity and should be extended to include other PDE5 inhibitors. It will also be necessary to extend the time window during which this combination is administered because DOX-induced cardiotoxicity occurs later in clinical therapy and different mechanisms may be responsible for the acute and chronic effects of DOX administered alone or in combination with PDE5 inhibitors.
Cardiovascular Pleiotropic Effects of PDE5 Inhibitors
Initially, PDE5 inhibitors were developed as potential antianginal agents, but early results in humans were disappointing and the focus of these drugs moved to the treatment of ED based on the findings of Ignarro et al 6 that nitric oxide and cyclic guanosine monophosphate were important mediators of penile erection. These findings resulted in the widespread use of PDE5 inhibitors for treating ED and have made these agents blockbuster drugs. Subsequently, sildenafil was shown to reduce pulmonary arterial pressure and is now clinically available to treat patients with pulmonary hypertension. 7 Several other cardiovascular uses of PDE5 inhibitors have emerged and are being actively pursued as possible clinical targets. These include treatment of patients suffering an acute myocardial infarction to reduce myocardial infarct size and to prevent the development of remodeling and the onset of heart failure, which normally occurs following an acute myocardial infarction. These targets are based on the landmark studies of Kukreja's group 8 in rabbits in which they showed that sildenafil produced an acute and delayed reduction in infarct size, similar to that of acute and delayed ischemic preconditioning, and in studies by Kass and colleagues 9 in which they demonstrated a reduction in the remodeling response in an animal model of heart failure. Although these are the two major areas of current interest, other potential targets are likely to emerge based on the potent smooth muscle relaxing and cytoprotective properties of PDE5 inhibitors. A summary of possible sites of action and pleiotropic effects of PDE5 inhibitors is shown schematically in Figure. 
